First patients test new cancer drug targeting specific tumor marker
Disease control
Completed
This first-in-human study tested a new drug called SAIL66 in 22 patients with advanced solid tumors that have a specific marker called CLDN6. The main goals were to find a safe dose and see how the body processes the drug, while also checking for any early signs that it might hel…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC